Clario Brand Guidelines: ERT, Bioclinica & a 2026 Move Into Thermo Fisher

A young name on an old business.

Clario is a young name on an old business. The company dates its history to 1972, but the name itself dates from 3 November 2021, when ERT announced that, following its merger with Bioclinica early in the second quarter of that year, the combined company would be called Clario. Clinical Research News reported the rebrand the same day, noting that the new name and brand identity took effect on that date. The announcement came from Philadelphia, the city Clario still gives on its press releases.

The two halves brought different specialities. ERT, which English Wikipedia describes as offering centralized cardiac and respiratory services for drug development and collecting electronic patient-reported outcomes, had grown largely through acquisitions. Wikipedia lists the Munich signal-processing company Biosigna in 2008; the research services division of CareFusion in 2010, which it says nearly doubled the company and brought a device manufacturing facility at Estenfeld in Germany; eClinical Insights in 2014; PHT Corporation in 2015; Exco InTouch in 2016; and ImageIQ, Biomedical Systems and iCardiac Technologies in 2017. Bioclinica, in the words of the 2021 announcement, was “a technological and scientific leader in medical imaging.”

Ownership changed several times along the way. Wikipedia says Genstar Capital of San Francisco took ERT private in 2012 and that the private equity firm Nordic Capital acquired it in 2016. Clario’s own 2025 press material says Astorg and Nordic Capital had co-owned the business since 2019, with Novo Holdings and Cinven as minority shareholders. The chief executive at the time of the rebrand, Joe Eazor, put the company’s case simply: “Clario is much more than the merger of two companies.”

Endpoints, measured five ways.

Clario describes what it sells as endpoint data: the measurements a clinical trial is designed to collect. Its website groups that work into five families — cardiac solutions; eCOA, or electronic clinical outcome assessments, the questionnaires and diaries patients and clinicians complete on phones, tablets or the web; medical imaging; respiratory measurements; and what it calls Precision Motion, wearable sensors for measuring movement. A further “trial enablement” group covers eligibility screening, reporting and analytics, and a source-document manager.

Several of these carry named products. The Precision Motion range is built around the Opal sensor system; the company lists an Opal V2R research-grade sensor and says more than 750 scientific publications reflect the system’s technical and clinical uses. In imaging, it names a SMART Submit tool for collecting and sharing de-identified images and an Image Redact AI tool for removing patient identifiers from videos, photos and PDFs. In respiratory work, it lists site-based and home spirometry, oscillometry, and measures of cough and lung sounds.

The company has kept buying. In May 2025 Clario announced it had completed the acquisition of WCG’s eCOA business, and its chief executive, Chris Fikry, linked the deal to an earlier purchase of NeuroRx, a specialist in neurology imaging analysis, presenting both as aimed at neuroscience trials. In February 2026 the company said it had received ISO 42001 certification, a management standard for artificial intelligence, in an audit by Schellman.

Clario also speaks about itself in large numbers. Its website says it has more than 50 years of experience, has worked on more than 30,000 clinical trial opportunities and operates in more than 100 countries and 100 languages; those are the company’s own figures. Its history page lists awards including Health IT Innovator of the Year, a CIO 100 award and an Omega customer-service award, without giving dates.

Software for science.

Life-sciences software is sold to scientists, clinicians, regulators and procurement teams at once, and the way these companies present themselves reflects that mixed audience. Their websites and brochures tend to show clean dashboards on laptops and tablets, molecule renderings and data charts, and people in lab coats or at clinic desks looking at screens. The product, in other words, is usually shown as an interface rather than an object.

The colour schemes follow the same logic. Many of these brands set one or two bright product colours against a lot of white space, so that charts, buttons and status labels stand out, and they use plain sans-serif type that stays legible in dense tables. Product families are often split into named “clouds,” “suites” or “platforms,” each with its own sub-brand, so a single company can carry dozens of product names under one mark.

Much of the selling happens in person. The sector gathers at trade conferences such as the DIA Global Annual Meeting, which brings together people working on drug development and regulation; Bio-IT World, which focuses on data and computing in life-sciences research; and SLAS, the laboratory-automation and screening society’s conference. Larger vendors also run their own customer summits, with keynote stages, product launches and user sessions; Medidata, for example, says its NEXT conference grew out of a user group for its Rave software.

Ownership matters too: several of the companies in this round have changed hands, and some have been bought by larger groups while keeping their own names. The guides in this round set out who founded each company, who owns it now and what it makes, and they mark clearly which statements rest only on the company’s own word.

A 2025 agreement, a 2026 close.

The private equity years ended in 2026. On 29 October 2025 Thermo Fisher Scientific announced a definitive agreement to acquire Clario Holdings from the shareholder group led by Astorg and Nordic Capital, with Novo Holdings and Cinven. Applied Clinical Trials reported on 24 March 2026 that the acquisition had been completed and that Clario would become part of Thermo Fisher’s Laboratory Products and Biopharma Services segment. The magazine also carried Thermo Fisher’s statement that Clario’s technology had supported roughly 70 percent of novel drug approvals by the FDA and EMA over the past decade; that is the buyer’s own figure.

The website now introduces the business as “Clario, part of Thermo Fisher Scientific,” while keeping its own name, navigation and newsroom. Its about page says the company fuses “deep scientific expertise and global scale” into what it calls “the broadest endpoint technology platform,” and its stated purpose, repeated across the site since the 2021 rebrand, is to “transform lives by unlocking better evidence.” Those are its words rather than independent findings.

The name has had to cover a wide spread of work: questionnaires on a patient’s phone, scans read by imaging specialists, spirometry at home and in clinics, and sensors worn during walking tests. Under one name since 2021, those lines sit side by side on the same website, each with its own product names beneath the company name.

For a design guide, Clario shows how a merged company can take one new name and a short purpose line while the specialised products underneath keep names of their own. Compare Thermo Fisher, its owner since 2026, and Signant Health, another clinical-trial technology company. For this guide we use a deep plum, a warm coral and soft mist with a sans, an unofficial interpretation; no product or logo is reproduced.

Keep Clario’s identity on hand — save it to a board in the Made Good inspiration library.